Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-19-001-L01-P).

Nursing (ANCC)
This activity is designated for 1.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

 

Objectives

At the conclusion of this activity, participants will be able to:
1. Describe the latest advances in the understanding of molecular features of tumors with ‘BRCAness’ or BRCA1/2 mutations and the rationale for the use of PARP inhibitors in these tumors.
2. Assess current and evolving data on the safety and efficacy of PARP inhibitors in ovarian cancer with BRCA1/2 and other DDR related mutations.
3. Examine the role of recommended genetic testing and counseling in patients with possible deleterious mutations in the DNA damage response pathway and its implications on treatment decisions and patient outcomes.
4. Discuss top clinical questions and patient cases pertaining to the treatment and management of advanced ovarian cancer patients with BRCA1/2 or other DDR-related mutations.

Target Audience

This initiative is targeted to gynecologic oncologists, medical oncologists, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other allied health professionals of the gynecologic oncology team who are attending the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:

Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Joan B. Fowler, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:

Ursula Matulonis, MD—has disclosed that she is a consultant for FUJIFILM, Geneos, Immunogen, Merck, and Mersana. She receives grant/research support from Merck.

Bradley J. Monk, MD, FACS, FACOG—has disclosed that he is a consultant for Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Conjupro, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precison Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, Inc., and VBL. He also is a member of the speakers’ bureaus for AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, and Tesaro, Inc.

Kathleen N. Moore, MD, MS–has disclosed that she is a consultant for Aravive, AstraZeneca, Clovis, Genentech/Roche, Immunogen, Janssen, Merck, OncoMed, Pfizer, Samumed, and Tesaro. She receives grant/research support from Genentech/Roche, Lilly, and PTC Therapeutics.

Peer Reviewers:

Jason Bergsbaken, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.

Angeles Alvarez Secord, MD, MHSc–has disclosed that she is a consultant for Aravive, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Merck, Mersana, Oncoquest, and Roche/Genentech. She receives grant/research support from AbbVie, Amgen, Astellas Pharma Inc., Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Prima Biomed, Roche/Genentech, Seattle Genetics, Inc, TapImmune and TESARO.

Lisa Arvine, RN, MSN, ANP-BC, WHNP-BC–disclosures to come.

Joanne K. Rash, MPAS, PA-C–disclosures to come.